Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $11.8 million.

  • Gyre Therapeutics' Cash & Equivalents rose 154.10% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 154.10%. This contributed to the annual value of $11.8 million for FY2024, which is 64.75% down from last year.
  • According to the latest figures from FY2024, Gyre Therapeutics' Cash & Equivalents is $11.8 million, which was down 64.75% from $33.5 million recorded in FY2023.
  • Over the past 5 years, Gyre Therapeutics' Cash & Equivalents peaked at $81.9 million during FY2020, and registered a low of $11.8 million during FY2024.
  • In the last 3 years, Gyre Therapeutics' Cash & Equivalents had a median value of $25.2 million in 2022 and averaged $23.5 million.
  • In the last 5 years, Gyre Therapeutics' Cash & Equivalents soared by 33.10% in 2023 and then plummeted by 64.75% in 2024.
  • Yearly analysis of 5 years shows Gyre Therapeutics' Cash & Equivalents stood at $81.9 million in 2020, then tumbled by 42.79% to $46.9 million in 2021, then crashed by 46.27% to $25.2 million in 2022, then surged by 33.10% to $33.5 million in 2023, then plummeted by 64.75% to $11.8 million in 2024.